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A B S T R A C T
Inﬂuenza epidemics annually cause substantial morbidity and mortality. For this reason, vaccination is oﬀered
yearly to persons with an elevated risk for complications. Assessments of the impact of vaccination are, however,
hampered by year-to-year variation in epidemic size and vaccine eﬀectiveness.
We estimate the impact of the current vaccination programme comparing simulations with vaccination to
counterfactual simulations without vaccination. The simulations rely on an age- and risk-structured transmission
model that tracks the build-up and loss of immunity over successive seasons, and that allows the vaccine match
to vary between seasons. The model parameters are estimated with a particle Monte Carlo method and ap-
proximate Bayesian computation, using epidemiological data on vaccine eﬀectiveness and epidemic size in the
Netherlands over a period of 11 years.
The number of infections, hospitalisations and deaths vary greatly between years because waning of im-
munity and vaccine match may diﬀer every season, which is in line with observed variation in inﬂuenza epi-
demic sizes. At an overall coverage of 21%, vaccination has averted on average 13% (7.2–19%, 95% range) of
infections, 24% (16–36%) of hospitalisations, and 35% (16–50%) of deaths. This suggests that vaccination is
mainly eﬀective in protecting vaccinees from infection rather than reducing transmission. As the Dutch popu-
lation continues to grow and age, the vaccination programme is projected (up to 2025) to gain in impact, despite
a decreasing infection attack rate.
1. Introduction
Inﬂuenza epidemics are the cause of a considerable number of
hospitalisations and deaths (World Health Organization, 2016;
Thompson et al., 2009; Iuliano et al., 2018). In the Netherlands, it has
been estimated in a comparative analysis of infectious diseases that the
disease burden of inﬂuenza is second only to pneumococcal disease
(Van Lier et al., 2016). Therefore, to reduce morbidity and mortality
from inﬂuenza virus infection, a free-of-charge vaccination is oﬀered
yearly to risk groups. These groups comprise children and adults with a
high risk of complications, and all persons over 60 years of age. In the
Netherlands and other high-income countries, the number of vaccine
doses required for the vaccination programme is expected to increase
over the next decade due to population growth and ageing.
An important step towards evaluating the impact of inﬂuenza vac-
cination programmes is to determine how many infections, hospitali-
sations and deaths are averted by vaccination. Such estimates are
available for the USA (Kostova et al., 2013; Foppa et al., 2015; Jackson
et al., 2015), assuming that incidence is inversely proportional to the
eﬀective vaccination coverage. However, this method underestimates
the true number of averted infections as it disregards the indirect eﬀects
of vaccination. To include these indirect eﬀects a dynamic transmission
model is required. Furthermore, such a model for seasonal inﬂuenza
should capture the variation between seasons, as infections that oc-
curred in previous seasons may aﬀect subsequent seasons (Woolthuis
et al., 2017). The variation between inﬂuenza seasons is largely caused
by the genetic drift of the inﬂuenza virus resulting in antigenic change
(Smith et al., 2004; Bedford et al., 2014). Previously infected in-
dividuals lose their immunity over the years, as the circulating virus
strain less and less resembles the virus strain that caused the initial
infection (Pease, 1987). As the antigenic drift can vary from season to
season, the rate at which naturally infected persons lose protection to
the circulating strain also varies. Henceforth, this rate will be called the
waning immunity rate, not to be confused with the waning of natural
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immunity. Variations in antigenic drift also lead to variations in how
well the vaccine matches the circulating strain. Both the varying
waning immunity rate and vaccine match result in variations in the
number of infections that occur during the subsequent inﬂuenza season.
The newly infected persons add to the population of previously infected
people that are still immune, setting a diﬀerent stage for the next season
when the waning immunity rate and vaccine match may be diﬀerent
again. Many dynamic models (Vynnycky et al., 2008; Pitman et al.,
2012; Rose et al., 2014; Gerlier et al., 2017) include this build-up and
loss of immunity over seasons, but the waning immunity rate is as-
sumed to be ﬁxed, leading to identical inﬂuenza seasons in simulations.
Other transmission models (Baguelin et al., 2013, 2015) consider iso-
lated inﬂuenza seasons, that do capture the seasonal variation but lack
the connection with the subsequent season.
We develop a stochastic transmission model, linking the season-to-
season dynamics and including variable loss of immunity, similar to
Woolthuis et al. (2017), to estimate how many infections, hospitalisa-
tions and deaths are prevented by the current vaccination programme
in the Netherlands. To this end, we ﬁrst estimate the infection attack
rates and vaccine eﬀectiveness in the Netherlands, based on surveil-
lance data, virology data, and literature. Subsequently, the distributions
of infection attack rate and vaccine eﬀectiveness are used to para-
meterise the transmission model. Using counterfactual simulations
without vaccination, the number of averted infections, hospitalisations
and deaths is estimated, in absolute numbers, as a fraction, and per
vaccine dose. Finally, it is assessed how these results are aﬀected by an
evolving demography.
2. Methods
We infer the fraction of the population that is infected during an
inﬂuenza season from multiple information sources, similar to the work
of McDonald et al. (2014). The main data source is the sentinel prac-
tices of NIVEL Primary Care Database that contains information on the
occurrence of inﬂuenza like illness (ILI) as reported by sentinel general
practitioners (GPs), stratiﬁed in 19 age groups. As not all of these pa-
tients are infected with inﬂuenza virus, a sample of ILI patients is tested
for inﬂuenza yielding the fraction of inﬂuenza virus infected ILI pa-
tients per age group and season. On the other hand, not all people in-
fected with inﬂuenza virus develop ILI (Carrat et al., 2008), and when
they do, the youngest and oldest age groups are more likely to visit their
GP (Friesema et al., 2009). All these fractions and probabilities taken
together, lead to an infection attack rate distribution based on data of
11 inﬂuenza seasons from 2003/2004 to 2014/2015 (with the excep-
tion of the pandemic season 2009/2010). The vaccine eﬀectiveness also
diﬀers from season to season. By combining published vaccine eﬀec-
tiveness values for 3 subtypes (Belongia et al., 2016) with the subtype
distribution over the 11 inﬂuenza seasons (Van Doorn et al., 2017), we
construct a vaccine eﬀectiveness distribution for a “composite strain”.
We do not distinguish between subtypes, but we model a general in-
ﬂuenza strain that leads to a typical infection attack rate (described by
the inferred distribution), and against which a trivalent vaccine has a
typical vaccine eﬀectiveness (described by the inferred distribution).
See SI section 1 for details on the inference procedure.
As we are interested in the number of infections, hospitalisations
and deaths over the entire season, we use time steps of 1 year. This
allows for the use of ﬁnal size calculations and for disregarding sea-
sonality. Each year, the structured compartmental model passes
through diﬀerent stages of a cycle (Fig. 1) to simulate the infection
attack rate and vaccine eﬀectiveness of that year. These outcome
measures over several years are compared to the inferred distributions
of infection attack rate and vaccine eﬀectiveness, to estimate the model
parameters.
Most model parameters are known or estimated from diﬀerent
sources (see SI section 3). For the demographic composition, data from
2015 is used (Statistics Netherlands, 2014). The population is
distributed over 2 risk classes (Tacken et al., 2014): persons at medical
risk of complications are categorized as “high risk” and the remainder
of the population falls in the “low risk” category (Fig. 2). All persons in
the high risk category and/or over 60 years old are invited for yearly
vaccination. Vaccination coverage (Tacken et al., 2014) in general in-
creases with age, and risk status. Overall, 21% of the total population is
vaccinated annually, 75% of which are persons of 60 years and older.
The vaccine take, i.e. the probability that a vaccinated person develops
an antibody response, decreases with age from 100% down to 30% for
the highest age class, estimated from observed seroconversion rates in
Fig. 1. Schematic overview of the inﬂuenza model. (A) Compartmental model
for discrete time steps of 1 year, with classiﬁcation according to vaccination and
infection status: susceptible (S and SV), immune through natural infection (R
and RV), and partially protected by vaccination (PV), where subscript V denotes
a vaccinated compartment. The model lacks an explicit infectious compartment
because of the use of ﬁnal size calculations. Each compartment is subdivided in
100 age classes (from 0 to 99 years of age), 2 risk groups (low and high) and 2
sexes (male and female). (B) Simulation cycle for each season consists of 3
stages. At the start of the season, people are vaccinated according to the vac-
cination coverage of their risk and age class, but whether they develop an an-
tibody response is captured by the vaccine take. During the season, infection is
mainly determined by the basic reproduction number R0 and the contact
structure between age and sex classes; how well vaccinated persons in the PV
compartment are protected against infection depends on the vaccine match. At
the end of the season, the population ages by 1 year and the immunity of some
previously infected people wanes. Vaccinated individuals return to an un-
vaccinated status as vaccine protection is assumed to last one season. Outcome
measures are the infection attack rate and vaccine eﬀectiveness of that season.
The outer ring shows the model parameters (that can be structured by age, risk
group and/or sex): demographic composition (age, risk, sex), vaccination cov-
erage (age, risk), vaccine take (age), contact matrix (age, sex), reproduction
number R0 (scalar), waning immunity rate (2 parameter distribution), and
vaccine match (2 parameter distribution). See SI section 2 for model details.
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diﬀerent age groups (Goodwin et al., 2006). The contact matrix quan-
tiﬁes how individuals tend to mix most with similarly aged individuals,
and how children and young adults have the highest contact rates (Van
de Kassteele et al., 2017).
The remaining parameters, i.e. the basic reproduction number R0,
waning immunity rate, and vaccine match (between 0 and 1), are ﬁtted
to the inferred infection attack rate and vaccine eﬀectiveness distribu-
tions. For parameter estimation, we use Approximate Bayesian
Computation combined with a particle Monte Carlo method that
minimizes the number of simulations (Lenormand et al., 2013). The
prior distribution for the basic reproduction number is fairly in-
formative, with a mean value of 1.8 (1.2–2.8, 95% range). In contrast to
the reproduction number, the waning immunity rate and the vaccine
match vary from season to season, and are identical for all age and risk
groups. Both are modelled as logitnormal distributions, each with two
parameters that have uniform prior distributions. The particles that
represent a sample from the posterior distribution, will be used for
counterfactual and forward simulations. See SI section 4 for details on
the parameter estimation.
The probability of hospitalisation and death after infection depends
strongly on the age and risk group of the infected person. McDonald
et al. (2018) reported mortality rates for 6 elderly age classes of 60
years and older in the Netherlands. As these data do not distinguish
between risk groups, we will use the distribution over the risk classes of
reported inﬂuenza mortality rates in the United Kingdom (Cromer
et al., 2014). This latter study deﬁnes risk groups as “at medical risk”
(corresponding to our high-risk group) and “not at medical risk” (cor-
responding to our low-risk group). The Dutch mortality rates above 60
years of age are multiplied with the fraction of inﬂuenza deaths oc-
curring in the hospital (Matias et al., 2016), and divided by the mor-
tality rate per hospitalisation (Cromer et al., 2014) to arrive at the
hospitalisation rates above 60 years of age. For mortality and hospita-
lisation rates under 60 years of age, we adopt the results of Cromer
et al. (2014). To estimate the probability of hospitalisation and mor-
tality after infection, all rates are divided by the group-speciﬁc infection
attack rate from our simulation results. All rates are modelled as normal
distributions.
Using the estimated parameters, inﬂuenza seasons are simulated
under the current vaccination programme. Each of the 1000 simula-
tions yields the infection attack rate, the number of hospitalisations and
the number of deaths in a season. To assess the eﬀect of the vaccination,
the simulations are repeated without vaccination. The diﬀerence yields
the number of infections, hospitalisations and deaths averted by vac-
cination. To study how these results are aﬀected by changing demo-
graphics, the model is simulated forward in time from 2015 to 2025.
Several model and parameter choices might aﬀect the results. We
conduct a sensitivity analysis to investigate the robustness of three
crucial choices. First, we study the eﬀect of the vaccine mechanism, viz.
an all-or-nothing vaccine (vaccine provides full protection to part of the
vaccinees) and a leaky vaccine (vaccine provides partial protection to
all vaccinees). The vaccine mechanism in our model lies in between
these two extremes. Secondly, we assumed consistent vaccination
where people with a vaccination indication persist in their choice
whether or not to be vaccinated. This is contrasted with random vac-
cination where people are randomly selected for vaccination each year.
And ﬁnally, the choice of prior distribution for the basic reproduction
number is evaluated. See SI section 5 for details on the sensitivity
analysis.
3. Results
3.1. Infection attack rate and vaccine eﬀectiveness
The estimated overall infection attack rate shows a large between-
season variability, with median infection attack rates ranging from 3 to
17 percent (Fig. 3). Taking these seasons to be representative for the
Dutch situation, we use the aggregated distribution over all seasons
with a median of 6.7% (2.6–17, 95% range) for parameter estimation.
We excluded the pandemic year 2009/2010, but inclusion of that
season would yield a similar infection attack rate of 6.9% (2.6–17),
demonstrating it was not an exceptional year in terms of the infection
attack rate.
To obtain the vaccine eﬀectiveness distribution, the subtype dis-
tribution over the seasons is combined with the reported vaccine ef-
fectiveness per subtype, yielding an overall vaccine eﬀectiveness of
45% (19–66). This is also an appropriate distribution for the
Netherlands, as the same estimation procedure for vaccine eﬀectiveness
values reported for the Netherlands (Darvishian et al., 2017) leads to an
average overall vaccine eﬀectiveness of 43% (8.8% minimum to 68%
maximum). More information on the results of both infection attack
rate and vaccine eﬀectiveness is provided in SI, section 1.
3.2. Parameter estimates
The parameter estimation procedure aims to match the simulated
distributions of infection attack rate and vaccine eﬀectiveness to the
inferred distributions. The set of posterior particles reproduces the
vaccine eﬀectiveness distribution well, yielding a median of 45%
(18–68, 95% range). The simulated infection attack rate of 6.9% (0–14)
reproduces the median well, although the distribution is less skewed
than inferred. Moreover, the autocorrelation of the simulated time
series of attack rates resembles the autocorrelation of the observed time
Fig. 2. Distribution of risk classes and vaccination coverage by
age group (Tacken et al., 2014). The population consists of low-
risk (light colours) and high-risk (dark colours) individuals. In-
dications to vaccinate are either medical risk of complications
(high risk) and/or age over 60 years. Of these indicated in-
dividuals, a part chooses to be vaccinated (purple) and the re-
mainder will not be vaccinated (green). See SI section 3 for tab-
ular data.
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series. This shows that the interseasonal dynamics are reproduced
where large and small epidemics can alternate because of the immunity
propagation from one season to the next (SI section 4).
The posterior distribution of the reproduction number R0 is 1.8
(1.3–2.7, median and 95% credible interval) which is largely de-
termined by the informative prior distribution. The average waning rate
is 0.19 (0.12–0.35) year−1 with a standard deviation of 0.031
(0.011–0.067) year−1. Taking the reciprocal of the waning rate, an
infected individual loses his immunity relative to the circulating strain
after 5.1 (2.9–8.2) years on average. The vaccine match is on average
0.56 (0.49–0.66) with a standard deviation of 0.11 (0.078–0.14). As
expected, parameter estimates are highly correlated (Fig. 4). Speciﬁ-
cally, the reproduction number and waning rate are reciprocally re-
lated. The vaccine match is positively correlated with the reproduction
number, although this seems speciﬁc for consistent vaccination (see SI
section 5).
The probabilities of hospitalisation and mortality after inﬂuenza
infection are calculated (Table 1) from the reported hospitalisation and
mortality rates (McDonald et al., 2018; Cromer et al., 2014) and our
infection attack rate results. Hospitalisation is highest in the very young
and elderly, while inﬂuenza mortality mainly occurs in elderly. High
risk persons have higher probabilities of hospitalisation and mortality
than similarly aged persons at low risk.
3.3. Number of averted infections, hospitalisations and deaths
Using the posterior parameter sets, the situation of 2015 is simu-
lated with and without vaccination. Results are reported as mean values
with the 95% range between brackets. The infection attack rate under
the current vaccination programme of 6.9% (0–14) would increase to
8.0% (0–14) if no one were vaccinated (Fig. 5), implying mean that
13% (7.2–19) of the infections are averted per year. Most infections are
averted in the older age groups of 60 years and older, which have the
highest proportion of vaccinated persons.
Fig. 3. Inferred infection attack rate in the
Netherlands for inﬂuenza seasons from 2003/2004 to
2014/2015 with the exception of the pandemic season
2009/2010, based on the sentinel practices and vir-
ology results. Violin plots show density with inter-
quartile range (dark area) and median value (dark
line) for separate seasons (red) and all seasons ag-
gregated (grey).
Fig. 4. Posterior distributions of the reproduction number R0, waning rate (mean and standard deviation) and vaccine match (mean and standard deviation). Density
plots (on-diagonal) show posterior (black line) and prior distribution (grey line). Scatter plots (oﬀ-diagonal) show pairwise relations.
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From the simulated infection attack rates in each age and risk group,
the numbers of hospitalisations and deaths are calculated using the
hospitalisation and mortality probabilities in Table 1. It is estimated
that with vaccination 389 (8–799) persons per million are hospitalised
yearly due to inﬂuenza complications. Vaccination averts 24% (16–36)
of the hospitalisations, mostly in the older age classes. The many hos-
pitalisations in the youngest age group are unaﬀected by vaccination, as
most of these occur in unvaccinated low-risk children.
Yearly, 122 (2–263) inﬂuenza deaths per million are expected under
the current vaccination programme. The majority (97%) of deaths oc-
curs in the age groups of 60 years and older. As these groups have the
highest vaccination coverage and the highest mortality probability after
infection, it is not surprising that the current vaccination programme is
most eﬀective in averting deaths: 35% (16–50) of the deaths are averted
by vaccination.
The current vaccination programme requires 3.56 million vaccine
Table 1
Probability distributions of hospitalisation p(hosp|infected) and mortality p(mort|infected) conditioned on infection, per risk and age group, of which mean and
(standard deviation) are reported here. These probabilities are based on mortality rates for age groups under (Cromer et al., 2014) and over (McDonald et al., 2018)
60 years of age, the fraction of inﬂuenza deaths occurring in the hospital (Matias et al., 2016), the mortality rate per hospitalisation (Cromer et al., 2014), and the
infection attack rate (inferred).
Age group (years) p(hosp|infected)×103 p(mort|infected)× 103
Low risk High risk Low risk High risk
0–4 21 (1.4) 21 (1.3) 0.0090 (0.00059) 0.36 (0.021)
5–14 0.87 (0.067) 5.6 (0.3) 0.00037 (0.000029) 0.096 (0.0050)
15–44 1.1 (0.039) 6.4 (0.26) 0.0070 (0.00024) 0.26 (0.010)
45–59 1.7 (0.051) 11 (0.46) 0.014 (0.00042) 0.56 (0.024)
60–64 3 (0.099) 9.5 (0.37) 0.084 (0.0037) 2.8 (0.12)
65–69 4.3 (0.15) 8.4 (0.29) 1.2 (0.042) 5.5 (0.19)
70–74 8 (0.18) 16 (0.35) 2.3 (0.050) 10 (0.23)
75–79 14 (0.5) 27 (0.99) 5.1 (0.19) 23 (0.86)
80–84 38 (1.3) 75 (2.5) 14 (0.48) 64 (2.2)
85–99 93 (2) 180 (3.8) 35 (0.74) 160 (3.3)
Fig. 5. Results of 1000 simulations for the 2015 situation, comparing the number of inﬂuenza infections (top), hospitalisations (middle) and deaths (bottom) per
inﬂuenza season for the current vaccination programme (colours) and a scenario without vaccination (grey tones). Left-hand panels show the overall distribution as a
histogram (bars) and density plot (line). Right-hand panels show the age distributions with median (line) and interquartile range (light area). Results per 5-year age
group and risk group are provided in SI section 6.
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doses for the 2015 population. Per 1000 vaccine doses 50 (27–72) in-
fections, 0.59 (0.38–0.89) hospitalisations and 0.31 (0.14–0.44) deaths
are averted.
3.4. Projections of vaccination programme impact
In the period 2015-2025, the total population is expected to increase
by 4% in The Netherlands (Statistics Netherlands, 2014). In the same
period, the fraction of persons of 60 years of age and older increases
from 24% to 29%. Assuming constant vaccination coverage per age and
risk group, the overall vaccination coverage would increase from 21%
to 24%, requiring 18% more vaccine doses.
The eﬀects of these demographic changes are studied by simulating
the model forward in time (Table 2). The infection attack rate is pro-
jected to decrease in an ageing population. The reason is that children
in school ages are considered to be the drivers of inﬂuenza transmis-
sion, while older age groups play a minor role (Worby et al., 2015). In
the same period however, the population increases in size. As a result,
the total number of inﬂuenza infections decreases only slightly. The
number of hospitalisations is approximately constant, while the number
of deaths increases, as these mainly occur in the growing elderly po-
pulation.
Combined with the scenario without vaccination, the numbers of
averted infections, hospitalisations and deaths are calculated. For most
outcomes, the percentages averted and the numbers averted per 1000
vaccine doses, are expected to increase. This is partly caused by the
higher fraction of older age groups leading to a larger role in the
transmission, and partly by the higher vaccination coverage leading to
additional indirect eﬀects.
3.5. Sensitivity analysis
The full analysis – consisting of parameter estimation, determining
hospitalisation and mortality probabilities, and simulations with and
without vaccination – is repeated for each model in the sensitivity
analysis (see SI section 5). We compare the number of averted infec-
tions, hospitalisations and deaths per 1000 vaccine doses (Fig. 6). The
three models that diﬀer in vaccine mechanism (default, all-or-nothing
and leaky) yield similar outcomes, possibly because diﬀerences would
only manifest at higher eﬀective reproduction numbers. For random
vaccination the impact of the vaccination programme is around 25%
lower than for consistent vaccination. The reason is that random vac-
cination leads to a lower estimated vaccine match, which is ultimately
caused by vaccine doses being squandered to persons that are already
immune due to natural infection. Consistent vaccination however more
closely resembles actual vaccination behaviour. With a mean prior for
the reproduction number of 1.6 and 2.0, the vaccination programme
impact is estimated to be slightly higher and lower, respectively, than
with the default mean prior of 1.8. In all cases – except for the random
vaccination model – the estimated interquartile and 95% ranges largely
overlap.
4. Discussion
To evaluate the impact of seasonal vaccination in terms of the
number of averted infections, hospitalisations, and deaths, we devel-
oped an inﬂuenza transmission model. The main strength of the model
is the combination of indirect eﬀects, season-to-season linkage, and
variation between inﬂuenza seasons, that together comprise a biologi-
cally plausible mechanism to describe inﬂuenza dynamics (Woolthuis
et al., 2017). The interseasonal variation and the parameter uncertainty
lead to estimated numbers of infections, hospitalisations and deaths
that vary from year to year, in line with the intrinsic variation of in-
ﬂuenza seasons. To assess the impact of inﬂuenza vaccination, we
evaluated counterfactual scenarios without vaccination. Essential to
this analysis, is the build-up and loss of immunity from one season to
the next. Without it, the immune fractions at the start of the season
have to be estimated for every age group. However, we cannot use these
estimates for the counterfactual scenario without vaccination, because
we expect the natural immunity levels in the population to be higher
without vaccination. By linking the seasons, the immunity propagation
and subsequent waning do lead to higher immune fractions (SI section
7). Also the distinction between age and risk groups that diﬀer in both
the risk of complications and vaccination coverage, is important to
evaluate the vaccination impact as accurately as possible.
We found that inﬂuenza vaccination at a coverage of 21% of the
total population, averts on average 13% of infections, 24% of hospita-
lisations, and 35% of deaths. In the US the same ranking is observed: on
average 10.2% of cases, 13% of hospitalisations, and 22% of deaths
may be averted by vaccination (Kostova et al., 2013; Foppa et al.,
2015). As the vaccination coverage in the US is even higher than in the
Netherlands, these lower averted fractions are presumably caused by
ignoring indirect eﬀects of vaccination in the US studies. In Germany,
two studies that do take the indirect eﬀects into account, show diﬀerent
results. Eichner et al. (2014) report that 37% of infections are averted
by vaccination, while Weidemann et al. (2017) ﬁnd that only 8.6% of
inﬂuenza-attributable medically attended acute respiratory infections
are averted. As they use diﬀerent models and diﬀerent parameter es-
timation procedures, it is diﬃcult to pinpoint what causes the large gap
between their results or the diﬀerence with our results. Studies from the
UK show vaccination eﬀects that are very similar to our results: they
ﬁnd 15% of infections, 26% of hospitalisations, and 37% of deaths are
Table 2
Simulated results for 2015 and 2025 under the current vaccination programme in the Netherlands. Mean values and 95% range between brackets.
2015 2025
Mean (95%) Mean (95%)
Population size 16.9× 106 17.5× 106
Vaccine doses 3.56× 106 4.22× 106
Infection attack rate 0.0689 (0–0.137) 0.0612 (0–0.128)
Total number of
Infections 1.17× 106 (25.9 ×103–2.32× 106) 1.07× 106 (0–2.25× 106)
Hospitalisations 6572 (132–13506) 6906 (0–14875)
Deaths 2058 (39–4443) 2473 (0–5528)
Averted by vaccination (%)
Infections 13 (7.2–19) 15 (8.2–27)
Hospitalisations 24 (16–36) 27 (13–35)
Deaths 35 (16–50) 37 (15–52)
Averted per 1000 vaccine doses
Infections 50 (27–72) 47 (25–82)
Hospitalisations 0.59 (0.38–0.89) 0.61 (0.30–0.78)
Deaths 0.31 (0.14–0.44) 0.34 (0.14–0.48)
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averted by the current vaccination programme, using a model based on
isolated seasons (Baguelin et al., 2013, 2015). The results per vaccine
dose however, are diﬀerent. The ﬁrst UK study (Baguelin et al., 2013)
reports 0.39 averted infection per vaccine dose, versus 0.050 in this
study. This discrepancy is caused by the higher infection attack rate of
25% in the study of Baguelin et al. (2013), versus 6.9% in the current
analysis. The same study reports 1.74 averted deaths per 1000 vaccine
doses due to generous mortality estimates by Hardelid et al. (2013),
while the later UK study (Baguelin et al., 2015) uses the estimates by
Cromer et al. (2014) for inﬂuenza deaths in the hospital, yielding 0.16
averted deaths per 1000 vaccine doses. Our estimate of 0.31 averted
deaths per 1000 vaccine doses are based on Dutch estimates (McDonald
et al., 2018) that also include mortality outside the hospital.
The average annual number of inﬂuenza deaths under the current
vaccination programme in the Netherlands is estimated to be 2058
(39–4443). This is in line with previously reported average estimates of
2704 by Van Asten et al. (2012) and 1956 by Van den Wijngaard et al.
(2012), and also the age distribution is well reproduced. It should be
noted though that these estimates as well as those by McDonald et al.
(2018) are based on all-cause mortality. Analyses using all-cause mor-
tality may falsely attribute some deaths to inﬂuenza, whereas analyses
using death records with a respiratory underlying cause may miss in-
ﬂuenza deaths (Dushoﬀ et al., 2006; Simonsen and Viboud, 2012). We
assumed that mortality rates in the diﬀerent risk groups is similar in
England and the Netherlands, as well as mortality below 60 years and
hospitalisation, due to lack of appropriate Dutch data. We believe that
both countries are comparable in terms of risk groups and vaccination
coverage.
For parameter estimation, some prior information was required due
to the interdependency between the reproduction number R0 and the
waning rate. We chose an informative prior for R0 for which in-
dependent estimates exist rather than assuming a waning rate without
conclusive data. In this way, we were able to estimate an average
waning immunity period of 5.1 (2.9–8.2, 95% CI) years. Only two other
studies also estimate the waning immunity. Thommes et al. (2014) ﬁnd
a lower value of 2.95 years for inﬂuenza A and a higher value of 15
years for inﬂuenza B. For a general inﬂuenza strain, Goeyvaerts et al.
(2015) report values of 2.3–3.1 years, but they assume vaccine pro-
tection lasts as long as natural immunity. We have assumed the vaccine
provides partial protection during one inﬂuenza season. Estimates that
are based on seroconversion rates after vaccination, are 0.8 years (Rose
et al., 2014) and 1.8 years (Eichner et al., 2014). Even if vaccine pro-
tection were to last longer than one season, the eﬀect is not expected to
be large because most vaccinees were already vaccinated the year be-
fore, according to our assumption of consistent vaccination.
We have assumed one generic inﬂuenza strain instead of modelling
speciﬁc strains and subtypes, similar to Goeyvaerts et al. (2015). As a
result, the infection attack rates from simulations have a narrower and
less skewed distribution, and show stronger autocorrelation between
seasons than observed (SI section 4). With suﬃcient data, an analysis
that distinguishes between inﬂuenza strains and subtypes could im-
prove the current analyses, but would also require assumptions on
competitive exclusion. But even with one generic strain, linking the
seasons and allowing for between-season variability is in our opinion a
step forward in inﬂuenza transmission modelling. Further progress
could be made by including the eﬀect of immunity on virus evolution
(Kucharski and Baguelin, 2017), changes in contact structure (Luca
et al., 2018), superspreading (Lloyd-Smith et al., 2005), or spatial
transmission (Gog et al., 2014), that could modulate the results.
A limitation of the model is that age distributions of the number of
infections, hospitalisations and deaths are nearly ﬁxed. First, the
transmission between age groups is dictated by a contact matrix; sec-
ondly, the age eﬀect of vaccination is absorbed in a (constant) vaccine
take; thirdly, the probabilities of hospitalisation and mortality are ﬁxed
per age and risk group, and ﬁnally, the waning rate is – although
variable by season – identical for all ages. The result is that in the si-
mulations the age-stratiﬁed distributions can diﬀer largely in magni-
tude, but little in shape (right-hand panels in Fig. 5). In reality however,
age-speciﬁc attack rates diﬀer per season, as the interplay between
vaccination and infection histories can aﬀect susceptibility and risk of
complications diﬀerently in each age group. These age patterns can be
captured by considering the diﬀerent age groups separately per season
(Baguelin et al., 2013; Weidemann et al., 2017). Such an alternative
analysis shows that the attack rates and immunity levels in each age
group are similar to those in the original analysis (SI section 7), al-
though they cannot be used for scenario analyses because of the lack of
season-to-season linkage.
Our results show that seasonal inﬂuenza vaccination is more eﬀec-
tive in averting inﬂuenza deaths than inﬂuenza infections. This in-
dicates that vaccination mainly works in protecting vaccinees rather
than decreasing transmission. A diﬀerent approach would be to focus
vaccination on the transmitters, i.e. children, so as to decrease the in-
fection attack rate and thereby protect the high-risk population in-
directly. This paradigm shift has ﬁrst been explored in Japan (Reichert
et al., 2001) and has recently been adopted in the United Kingdom
(Pebody et al., 2015) where programmes to vaccinate children in school
ages are implemented. Furthermore, this study shows that the impact of
the current vaccination progamme is expected to increase over the next
decade, despite a projected decrease in the infection attack rate. The
vaccination coverage however, was assumed to remain constant per risk
and age group, even though actual estimates suggest it is decreasing
(Tacken et al., 2015). With the model presented here, it is possible to
evaluate modiﬁcations to the current vaccination programme, such as a
paediatric vaccination programme or a decreasing vaccination coverage
in elderly.
Fig. 6. Results of sensitivity analyses, comparing the
number of averted infections, hospitalisations and
deaths per 1000 vaccine doses for the baseline model
(red), a model with an all-or-nothing vaccine (dark
red), a model with a leaky vaccine (orange), a model
with random vaccination (green), the default model
with a mean prior reproduction number of 1.6 (light
blue) and 2.0 (dark blue). Shown are mean (dark
point), interquartile range (dark line) and 95% range
(light line).
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